Why the study?
Do anticytokine and broader immune modulation therapies slow disease progression in patients with chronic heart failure?
Do anticytokine and broader immune modulation therapies slow disease progression in patients with chronic heart failure?
Despite the failure of targeted anti-TNF-alpha therapies, broader immune modulation strategies remain a promising therapeutic avenue for chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Caution against anti-TNF use in chronic HF; leaves open broader immune modulation for prospective trials.
Haehling et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: